A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density - Test2 - elhamkhani - TriplyDB

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

http://www.wikidata.org/entity/Q28247445

about

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Sclerostin Inhibition in the Management of Osteoporosis New insights into treatment of osteoporosis in postmenopausal women Emerging Therapies for Osteoporosis Male Osteoporosis in the Elderly Denosumab for the treatment of osteoporosis Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis Recent advances in the pathogenesis and treatment of osteoporosis Efficacy of Osteoporosis Therapies in Diabetic Patients.Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.Chronic kidney disease and the skeleton.Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.LRP receptor family member associated bone disease Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.Connecting the Dots: Linking Osteocyte Activity and Therapeutic Modulation of Sclerostin by Extending a Multiscale Systems Model.Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro CORR Insights(®): Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?Mutations in Known Monogenic High Bone Mass Loci Only Explain a Small Proportion of High Bone Mass Cases A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.Rescuing failed oral implants via Wnt activation Serum sclerostin levels in renal cell carcinoma patients with bone metastases Sclerostin's role in bone's adaptive response to mechanical loading.Osteoporosis Therapy: Bone Modeling during Growth and Aging.A look behind the scenes: the risk and pathogenesis of primary osteoporosis.Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders.Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.Appropriate models for novel osteoporosis drug discovery and future perspectives.Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.New management options for osteoporosis with emphasis on SERMs.Protective alleles and modifier variants in human health and disease.Endothelin Signaling in Bone.Sclerostin: More than a bone formation brake.Normal bone density and trabecular bone score, but high serum sclerostin in congenital generalized lipodystrophy.From restoration to regeneration: periodontal aging and opportunities for therapeutic intervention.The Utility of Biomarkers in Osteoporosis Management.

P2860

Q26744599-222993E3-AEAB-4607-AA4C-91893252010A Q26750713-16BE05AD-D4EC-4643-BB28-B68E9D2647F2 Q26777910-D2A76059-AA04-4AEF-8D27-0569F43FAB6C Q26782109-AB90E8B6-21A8-4C75-B620-91E6E50C04D6 Q26784352-825A5DAD-6D50-4205-B467-1CA58F3B7634 Q27009275-0DAA6BA2-F4FA-4752-8F49-0FAC27C60FD3 Q27022580-D280105B-6C9A-48BE-A18E-58CC03A43654 Q30248661-D2C13AF0-45B9-4255-B43D-DCC4FBBD2B83 Q30248776-C8D4EB50-ED90-424B-B91F-8430AA5D3EB7 Q30713102-7A1D76A6-5C66-42FE-BA9B-C70771C4A810 Q33812106-58832BD9-68FC-4528-9236-D7218475C2DB Q35507830-0B9B0DF5-6EBC-4F65-B602-ED0C65E68CDA Q35694436-B6DC9C3D-7636-417A-99EF-5D801DFF12EE Q35755179-5E8A8587-C936-4AFE-98E2-FE7449F52FC0 Q35854185-CA6F8476-F91E-411A-B867-DBB3E34FE9BF Q36005849-0E61C8E3-88FA-46D3-8A70-8B74CE2E7B03 Q36104700-4CA8634C-EFA8-411A-958D-0ECD8CAED58B Q36118302-19B57941-BAC9-47D9-8B71-24D1BC869B92 Q36198506-DF6168DD-C8AA-4A97-8FEA-E92C98619792 Q36256294-9686A94B-C09A-4EEE-89CE-581E2155CF91 Q36746795-BF451BC0-EAC5-45C1-83A4-AEEB861EFC8A Q36799783-BD797A11-2F22-4295-B500-BC6817C3784E Q36973896-1A4C135B-522A-4F18-8BD8-456683D3C70F Q37152121-326E456D-3F8A-4194-8115-E1198D822893 Q37282121-EC48381C-235E-47DB-9C45-7B96D861B405 Q37684437-AAC75DDE-7B71-4A7E-9DDE-E75AFDB262D3 Q37689421-5404CFFD-7897-4F1D-B2D1-C7FFD6346F2D Q38434317-0C639474-233B-41EB-BA63-B8F0BC53BC69 Q38470745-C394824D-A7FA-4F4A-950A-ABCCC7FB6C46 Q38569480-9A3B7338-E0E5-4905-B097-7FD44C24500C Q38570326-5E604C17-0804-43DA-AF31-241A0B4A1708 Q38610545-E8AB18F5-03DE-495B-BF69-3B2D0369B461 Q38611601-3A0C8D92-9080-4E07-A90A-2384E6C5DD69 Q38616755-A781CE39-6E43-4F0E-A7B5-2C92D9354EEB Q38616791-9B820E57-AF4C-41C1-8CB5-E4B3E00AC45F Q38764798-4B65E1EF-0260-45D1-987C-C689A7E6519F Q38810985-8F181F0F-CE48-49F4-9833-F9BEADE74B18 Q38846381-F0373C4D-87D3-4FED-BC97-3786FD299CE4 Q38921820-AAF9F863-F3FA-4A4C-9DE6-9AEBEAB294E1 Q38921875-ECC29859-0E44-4C7D-86CE-881A7354221B

P2860

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

http://www.wikidata.org/entity/Q28247445

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A randomized, double-blind pha ...... with low bone mineral density

@ast

A randomized, double-blind pha ...... with low bone mineral density

@en

A randomized, double-blind pha ...... with low bone mineral density

@nl

type

label

A randomized, double-blind pha ...... with low bone mineral density

@ast

A randomized, double-blind pha ...... with low bone mineral density

@en

A randomized, double-blind pha ...... with low bone mineral density

@nl

prefLabel

A randomized, double-blind pha ...... with low bone mineral density

@ast

A randomized, double-blind pha ...... with low bone mineral density

@en

A randomized, double-blind pha ...... with low bone mineral density

@nl

P1433

Q28247445-973A9B05-44EF-459C-BFAC-0623B4FE086F

P1476

Q28247445-3C6118D4-39E0-4321-839C-B59BAD6102FA

P2093

Q28247445-200A16EC-556B-449A-8C1C-40C5E84CE6C0

Q28247445-2FB0E11C-4E87-4E82-9489-F3291206E5BB

Q28247445-37ED6819-22A3-463F-9C7D-10253EB42A99

Q28247445-4531A682-D8EB-4BB1-965D-23596C8BAD17

Q28247445-46C7EC5C-9E74-48BA-87E0-A8C051A48D2E

Q28247445-7E60BE79-7DCA-4C35-83E6-DD43BCAC51A0

Q28247445-9f50e51a-4cd3-49e7-5c9f-e8dcfa7a88e5

Q28247445-C93F0135-C68E-4490-89FD-5ACADFB29EBB

Q28247445-E554A0B9-1F62-4F7D-BAD6-E3A2F4CF7CDB

Q28247445-E604BB85-FB3C-4B8D-9705-E5883B846954

P2860

Q28247445-011D7428-136C-4229-8DD1-DCDC6E1C0316

Q28247445-02899836-7201-4739-A86B-C382F69F73F4

Q28247445-047F88C5-5799-4B5E-9EA6-5982479F589F

Q28247445-0888B653-1C40-49D7-B137-606FA779379B

Q28247445-102CBD7E-F024-46BF-AED5-9318101DA7ED

Q28247445-14177A50-C66D-473C-AFDA-BCFEE5D856D4

Q28247445-35EC0438-ACE7-4ADF-A62F-3969E4EC45CB

Q28247445-4ADF1192-3FDE-42C9-AB3A-6265296F013F

Q28247445-4EF7BFA4-1EE6-4BA4-9754-F53DCCE561E2

Q28247445-6BB8DC0F-52E3-4476-887B-C5AEDEF2B81D

P304

Q28247445-B5D5BBB1-5484-4ED7-A79A-70C394A7876F

P31

Q28247445-4226AA9A-E3E5-4018-98EC-5C991A8BF3E6

Q28247445-99C2AC8D-D6CB-469D-B30E-F04E70281A02

P3181

Q28247445-06E9E33E-459A-44D6-B69A-C1CCC67C3B93

P356

Q28247445-014564EA-F804-47A0-A9CE-FD1E9E1D1CE6

P407

Q28247445-B234C253-A539-47E9-A1D2-B2B8BD215022

P433

Q28247445-F8005D3F-1AE5-416F-A482-9F5009A43774

P478

Q28247445-EDD27F01-9AF4-4C0F-ABAB-B357E12C36AB

P577

Q28247445-2809E0E6-6FD0-4223-9557-E1FA21A24029

P698

Q28247445-51DFD21A-FDE3-4C74-A205-603DB13115BD

P921

Q28247445-A96404A2-A91F-4D7E-B323-ACC6D617F535

Q28247445-E992FBDF-871B-4D28-9359-115251255975

P3181

P356

P1433

Journal of Bone and Mineral Research

P1476

A randomized, double-blind pha ...... with low bone mineral density

@en

P2093

Alan Y Chiang

http://www.w3.org/2001/XMLSchema#string

Bruce H Mitlak

http://www.w3.org/2001/XMLSchema#string

Charles T Benson

http://www.w3.org/2001/XMLSchema#string

Deborah A Robins

http://www.w3.org/2001/XMLSchema#string

Hideaki Sowa

http://www.w3.org/2001/XMLSchema#string

Jahangir Alam

http://www.w3.org/2001/XMLSchema#string

John H Krege

http://www.w3.org/2001/XMLSchema#string

Leijun Hu

http://www.w3.org/2001/XMLSchema#string

Michael A Bolognese

http://www.w3.org/2001/XMLSchema#string

Robert R Recker

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

Regulation of Wnt/β-catenin signaling within and from osteocytes

Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway

Sclerostin: current knowledge and future perspectives.

Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: a systematic review.

Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives

A reference standard for the description of osteoporosis.

P304

216-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1230183

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/JBMR.2351

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25196993

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial